Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma

J Pediatr Hematol Oncol. 2012 Oct;34(7):e295-7. doi: 10.1097/MPH.0b013e3182441588.

Abstract

We report on the use of single-agent docetaxel (100 mg/m(2) in children >10 kg, 3.3 mg/kg in children <10 kg), given as a 1-hour infusion at 21-day intervals in 5 children with relapsed or refractory hepatoblastoma. One patient achieved complete remission of pulmonary metastases after 2 courses of docetaxel and remains well 10 years later, after completion of 13 courses of docetaxel and whole-lung radiotherapy. One patient showed a partial response to docetaxel based on α-fetoprotein measurements. Docetaxel shows some activity in progressive hepatoblastoma in this small case series and is a potential drug for future study in this disease.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Docetaxel
  • Female
  • Hepatoblastoma / drug therapy*
  • Humans
  • Infant
  • Liver Neoplasms / drug therapy*
  • Male
  • Taxoids / therapeutic use*

Substances

  • Antineoplastic Agents
  • Taxoids
  • Docetaxel